These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 37709229)

  • 1. Effects of the glycosylation of the receptor binding domain (RBD dimer)-based Covid-19 vaccine (ZF2001) on its humoral immunogenicity and immunoreactivity.
    Wang X; Shi L; Wang Y; Chen J; Yang Z; Liu C; Liu X; Li Y; Zhang C; Sun A; Yan H; Sun H
    Int J Biol Macromol; 2023 Dec; 253(Pt 3):126874. PubMed ID: 37709229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust and protective immune responses induced by heterologous prime-boost vaccination with DNA-protein dimeric RBD vaccines for COVID-19.
    An Y; Zhao G; Duan H; Zhang N; Duan M; Xu S; Liu X; Han Y; Zheng T; Li X; Hou J; Zhang Z; Bi Y; Zhao X; Xu K; Dai L; Wang B; Gao GF
    J Med Virol; 2023 Jul; 95(7):e28948. PubMed ID: 37436839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
    Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD
    mBio; 2021 May; 12(3):. PubMed ID: 33975938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates.
    An Y; Li S; Jin X; Han JB; Xu K; Xu S; Han Y; Liu C; Zheng T; Liu M; Yang M; Song TZ; Huang B; Zhao L; Wang W; A R; Cheng Y; Wu C; Huang E; Yang S; Wong G; Bi Y; Ke C; Tan W; Yan J; Zheng YT; Dai L; Gao GF
    Emerg Microbes Infect; 2022 Dec; 11(1):1058-1071. PubMed ID: 35311493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice.
    Barbey C; Su J; Billmeier M; Stefan N; Bester R; Carnell G; Temperton N; Heeney J; Protzer U; Breunig M; Wagner R; Peterhoff D
    Eur J Pharm Biopharm; 2023 Nov; 192():41-55. PubMed ID: 37774890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2.
    Nguyen K; Chakraborty S; Mansbach RA; Korber B; Gnanakaran S
    Viruses; 2021 May; 13(5):. PubMed ID: 34067878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
    PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective RBD-dimer vaccines against SARS-CoV-2 and its variants produced in glycoengineered Pichia pastoris.
    Zhao T; Liu S; Wang P; Zhang Y; Kang X; Pan X; Li L; Li D; Gao P; An Y; Song H; Liu K; Qi J; Zhao X; Dai L; Liu P; Wang P; Wu G; Zhu T; Xu K; Li Y; Gao GF
    PLoS Pathog; 2024 Aug; 20(8):e1012487. PubMed ID: 39213280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Rong Y; Wang X; Mao W; Chen M; Wang S; Wang PG; He Y; Kong Y
    Chem Commun (Camb); 2023 Feb; 59(13):1797-1800. PubMed ID: 36722411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor-Binding Domain (RBD) Antibodies Contribute More to SARS-CoV-2 Neutralization When Target Cells Express High Levels of ACE2.
    Farrell AG; Dadonaite B; Greaney AJ; Eguia R; Loes AN; Franko NM; Logue J; Carreño JM; Abbad A; Chu HY; Matreyek KA; Bloom JD
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
    Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
    Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
    Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
    Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells.
    Zheng L; Ma Y; Chen M; Wu G; Yan C; Zhang XE
    Biochem Biophys Res Commun; 2021 Nov; 579():69-75. PubMed ID: 34592572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Targeted RIG-I Receptor 5'Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine.
    Bai Y; An C; Zhang X; Li K; Cheng F; Cui B; Song Z; Liu D; Zhang J; He Q; Liu J; Mao Q; Liang Z
    Viruses; 2023 Apr; 15(5):. PubMed ID: 37243185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.